Related Experiment Videos
Immunological evaluation in patients with urological cancers.
European Urology
|January 1, 1977
Summary
This study found significant immune system deficiencies in urological cancer patients, particularly with prostatic, bladder, and renal cancers. Treatment improved immune response, and immune depression correlated with higher metastasis and recurrence rates.
Area of Science:
- Immunology
- Oncology
- Urology
Background:
- Urological cancers, including prostatic, bladder, and renal, can significantly impact patient immune status.
- Assessing immunological competence is crucial for understanding cancer progression and treatment response.
Purpose of the Study:
- To evaluate the immunological competence in patients with urological cancers.
- To investigate the relationship between immune status, tumor characteristics, and treatment outcomes.
Main Methods:
- Utilized skin tests and serum immunoelectrophoresis to assess cell-mediated immunity and immunoglobulin levels.
- Analyzed data from 100 patients diagnosed with various urological malignancies.
Main Results:
- Observed cell-mediated immunodepression in 93.3% of prostate, 68.6% of bladder, and 38.4% of renal cancer patients.
- Found elevated immunoglobulin levels in 80% of prostate, 31.3% of bladder, and 23% of renal cancer cases, with IgA prominent in prostate cancer.
- Demonstrated a correlation between immunodepression and tumor stage in bladder and renal cancers.
- Noted significant improvement in skin test reactivity post-treatment.
- Identified a higher incidence of metastases and recurrences in immunodepressed patients.
Conclusions:
- Urological cancers are frequently associated with significant immune system impairment.
- Treatment can restore immune reactivity, suggesting a potential therapeutic target.
- Immune depression is a prognostic indicator for increased metastasis and recurrence risk in urological cancers.